TABLE 2.
Multivariable Models Evaluating Actual Changes In SBP and DBP Associated With the Initiation of RA Therapiesa
| Δ in Systolic BP at 6 mo |
Δ in Diastolic BP at 6 mo |
|||
|---|---|---|---|---|
| B (95% CI) | P | B (95% CI) | P | |
| Methotrexate | (Reference) | (Reference) | ||
| Prednisone | 0.30 (−0.20 to 0.81) | 0.24 | 0.55 (0.24 to 0.87) | 0.001 |
| Leflunomide | 1.82 (1.15 to 2.50) | <0.001 | 1.63 (1.22 to 2.06) | <0.001 |
| Anti-TNF | 0.88 (0.29 to 1.48) | 0.003 | 0.70 (0.33 to 1.07) | <0.001 |
| Sulfasalazine | −0.030 (−0.77 to 0.71) | 0.94 | 0.69 (0.23, b1.15) | 0.003 |
| Hydroxychloroquine | −0.31 (−0.88 to 0.26) | 0.28 | 0.098 (−0.26 to 0.45) | 0.59 |
| Age (per 1 y) | 0.059 (0.042 to 0.076) | <0.001 | −0.13 (−0.14 to −0.12) | <0.001 |
| Female | 0.73 (0.21 to 1.25) | 0.006 | 1.64 (1.32 to 1.96) | <0.001 |
| Black | 1.28 (0.83 to 1.72) | <0.001 | 0.99 (0.71 to 1.27) | <0.001 |
| BMI (per 1 kg/m2) | 0.13 (0.097 to 0.16) | <0.001 | 0.020 (0.002 to 0.038) | 0.03 |
| Current smoking | 0.28 (−0.16 to 0.72) | 0.21 | 0.59 (0.31 to 0.86) | <0.001 |
| Hypertension | 2.84 (2.37 to 3.31) | <0.001 | 1.11 (0.82 to 1.40) | <0.001 |
| Diabetes | 0.23 (−0.16 to 0.61) | 0.23 | −0.89 (−1.13 to −0.66) | <0.001 |
| History of heart attack | −1.76 (−2.37 to −1.15) | <0.001 | −0.75 (−1.12 to −0.37) | <0.001 |
| Interstitial lung disease | −1.06 (−1.55 to −0.57) | <0.001 | −0.24 (−0.54 to 0.067) | 0.07 |
| CHF | −2.21 (−2.73 to −1.68) | <0.001 | 1.03 (1.36 to −0.70) | <0.001 |
| Comorbidity score (per unit) | −0.25 (−0.37 to −0.11) | <0.001 | −0.22 (−0.31 to −0.14) | <0.001 |
| Concurrent sulfasalazine | 1.20 (0.62 to 1.78) | <0.001 | 0.27 (−0.089 to 0.63) | 0.14 |
| Concurrent methotrexate | −0.66 (−1.17 to −0.16) | 0.01 | −0.15 (−0.46 to 0.16) | 0.35 |
| Concurrent TNF | 0.0061 (−0.53 to 0.54) | 0.98 | 0.29 (−0.042 to 0.62) | 0.09 |
| Concurrent leflunomide | 1.65 (0.95 to 2.36) | <0.001 | 1.02 (0.58 to 1.47) | <0.001 |
| Disease >5 y | −0.10 (−0.45 to 0.25) | 0.20 | −0.41 (−0.63 to −0.19) | <0.001 |
| Baseline SBP | −0.54 (−0.55 to −0.53) | <0.001 | — | |
| Baseline DBP | — | −0.49 (−0.50 to −0.48) | <0.001 | |
| Prior ΔSBP | −0.20 (−0.21 to −0.19) | <0.001 | — | |
| Prior ΔDBP | — | −0.23 (−0.24 to −0.22) | <0.001 | |
| Antihypertensives (no use) | (Reference) | (Reference) | ||
| Prior and current use | −0.57 (−1.05 to −0.081) | 0.02 | −0.64 (−0.94 to −0.34) | <0.001 |
| New Use | −0.96 (−1.71 to −0.21) | 0.01 | −0.37 (−0.84 to 0.093) | 0.12 |
a
Also included in the models but non-significant and not shown in tables (P > 0.05): concurrent prednisone, concurrent HCQ, concurrent TNFi, CKD, any malignancy, lung cancer, other lung disease, ACPA positivity, RF positivity, and CRP.
CI indicates confidence interval; CKD, chronic kidney disease; HCQ, hydroxychloroquine.